Search Results 271-280 of 18472 for Relapse
A Study to Evaluate Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell ...
... relapse prevention strategies. The Mayo Clinic Nicotine Dependence Center at Mayo Clinic's campus in Minnesota was one of the first centers in the United ...
immunotherapy and to assess selection differences, treatment sequencing and outcomes from salvage therapy after first or subsequent novel immunotherapy.
The primary aim of this study is to define a comprehensive digital phenotype that predicts risk for near-future relapse or relapse in alcohol use in patients ...
The purpose of this study is to evaluate the safety and effectiveness CTX110 in subjects with relapsed or refractory B cell malignancies. Participation ...
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma · Overview · Participation eligibility · Participating Mayo Clinic locations.
GPRC5D-directed CAR T Cell Therapy in Participants with Relapsed or Refractory Multiple Myeloma. Print details. Share; Facebook · Twitter. Overview ...
A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared with Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients with Relapsed or ...
ROCHESTER, Minn. — Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T-cell therapy, ...
... relapsed acute leukemia (AML or ALL) for future biological studies. By accruing samples both at initial diagnosis and at relapse, we will be able to ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.